Mirum Pharmaceuticals, Inc.
For the period ended Dec 31, 2025. Filed Feb 25, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 25, 2026
MIRM$94.42+1.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders’ Equity
| Common Stock · AdditionalPaid-InCapital · AccumulatedDeficit · AccumulatedOtherComprehensiveIncome (Loss) · TotalStockholders’Equity | ||||||
|---|---|---|---|---|---|---|
| Shares · Amount | ||||||
| Balance as of December 31, 2022 | 36,956,345 | $4 | $535,074 | $(392,824) | $(217) | $142,037 |
| Issuance of common stock in private placement, net of issuance costs of $7,796 | 8,000,000 | 1 | 202,203 | — | — | 202,204 |
| Issuance of common stock in at-the-market offerings, net of issuance costs of $518 | 658,206 | — | 14,480 | — | — | 14,480 |
| Issuance of common stock in connection with asset acquisition | 231,624 | — | 5,188 | — | — | 5,188 |
| Issuance of common stock in connection with equity award plans | 760,226 | — | 8,279 | — | — | 8,279 |
| Issuance of common stock in connection with employee stock purchase plan | 116,742 | — | 2,191 | — | — | 2,191 |
| Stock-based compensation | — | — | 35,845 | — | — | 35,845 |
| Net loss | — | — | — | (163,415) | — | (163,415) |
| Other comprehensive income | — | — | — | — | 1,861 | 1,861 |
| Balance as of December 31, 2023 | 46,723,143 | $5 | $803,260 | $(556,239) | $1,644 | $248,670 |
| Issuance of common stock in connection with equity award plans | 1,489,510 | — | 15,059 | — | — | 15,059 |
| Issuance of common stock in connection with employee stock purchase plan | 125,443 | — | 2,640 | — | — | 2,640 |
| Stock-based compensation | — | — | 49,230 | — | — | 49,230 |
| Net loss | — | — | — | (87,942) | — | (87,942) |
| Other comprehensive loss | — | — | — | — | (2,017) | (2,017) |
| Balance as of December 31, 2024 | 48,338,096 | $5 | $870,189 | $(644,181) | $(373) | $225,640 |
| Issuance of common stock in connection with equity award plans | 3,450,566 | — | 36,200 | — | — | 36,200 |
| Issuance of common stock in connection with employee stock purchase plan | 106,977 | 3,942 | 3,942 | |||
| Conversion of convertible notes, net | 752 | — | 24 | — | — | 24 |
| Stock-based compensation | — | — | 71,523 | — | — | 71,523 |
| Net loss | — | — | — | (23,363) | — | (23,363) |
| Other comprehensive income | — | — | — | — | 724 | 724 |
| Balance as of December 31, 2025 | 51,896,391 | $5 | $981,878 | $(667,544) | $351 | $314,690 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.